SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Leads Biolabs Doses First Patient in LBL-047 Phase I Part B Trial

Leads Biolabs says it has dosed the first patient with systemic lupus erythematosus in Part B of its Phase I trial of LBL-047, a BDCA2/TACI bifunctional fusion protein.

Related stories